# A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

> **NCT00669591** · PHASE2 · COMPLETED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bavituximab

## Key facts

- **NCT ID:** NCT00669591
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669591, "A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00669591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*